Journal article

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Hope S Rugo, Jean-Pierre Delord, Seock-Ah Im, Patrick A Ott, Sarina A Piha-Paul, Philippe L Bedard, Jasgit Sachdev, Christophe Le Tourneau, Emilie MJ van Brummelen, Andrea Varga, Roberto Salgado, Sherene Loi, Sanatan Saraf, Dina Pietrangelo, Vassiliki Karantza, Antoinette R Tan

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2018

Grants

Funding Acknowledgements

The authors thank the patients and their families, study investigators, and site personnel and Roger Dansey (Merck & Co., Inc., Kenilworth, NJ) for critical manuscript review. Medical writing and/or editorial assistance was provided by Sarita S. Shaevitz, PhD, and Amy McQuay, PhD, of the ApotheCom pembrolizumab team (Yardley, PA). This assistance was funded by Merck & Co., Inc., Kenilworth, NJ. Funding for this research was provided by Merck & Co., Inc., Kenilworth, NJ.